6 mg retatrutide Retatrutide 6mg

A 2024 study by Hathaway et al , which investigated more than 16 000 patients over a period of six years, first raised ocular safety issues related to semaglutide

The mediation proportions were 26.1% for blood glucose, 11.8% for insulin level, 6.6% for C-reactive protein, 0.6% for cholesterol (not significant), and 0.8% for systolic blood pressure (not significant)

The main difference between the two is that Wegovy is specifically approved for weight loss, while Ozempic is approved to treat Type 2 diabetes

The $149 per month oral entry price is competitive but involves consultation costs on top that most cash-pay patients do not account for when calculating their actual monthly spend

Dietary supplements are not intended to replace prescription GLP-1 medications